Read more
History is an erudite teacher, from which we can learn invaluable lessons, both positive and negative. This is especially true for drug discovery and development. While creativity demands we think outside of the box, past successes and failures in creating medicines are gifts that keep on giving. Creation of human medicines involves so many scientific and medical disciplines that history is our indispensable resources of institutional knowledge. This volume in a new series sheds light on successes to emulate and pitfalls to avoid in oncology drug discovery. The series editor blends education with engaging content for aspiring drug developers and helps to foster a deeper understanding.
Key Features - Aims to integrate biology, chemistry, medicine, and history, which mirrors the multidisciplinary nature of drug development
- By targeting the next generation drug developers and making efforts to include narrative and historical elements, it differentiates itself from pure technical texts
- Using history to contextualize drug discovery helps readers to understand why certain strategies worked or failed
- The inclusion of chemical structures in Chapter 7 makes the book more substantial for scientists with a chemistry background
- The focus on novel approaches enhances the relevance of the book for the future.
List of contents
Preface. Chapter 1: The Origins of Cancer. Chapter 2: Chemotherapies: Pyrrhic Victory. Chapter 3: Targeted Cancer Therapy: Protein Kinase Inhibitors. Chapter 4: Biologic Cancer Drugs. Chapter 5: New Modalities of Cancer Treatments. Chapter 6: Artificial Intelligence in Cancer Medicine. Chapter 7: Reflections. Chapter 8: Chemical Structures of Key Cancer Drugs. Bibliography. Index
About the author
Dr. Jie Jack Li is an established chemist with over 30 years of experience in both medicinal chemistry and process chemistry. He is also widely published as an author or co-author of 34 peer-reviewed articles, 12 patents, and 35 books. Dr. Li worked at Pfizer, BMS, and Revolution Medicines in oncology, antivirals, metabolic disease, CNS, anti-inflammatory, and dermatology, targeting enzymes, receptors, or ion channels. Dr. Li was also a professor at the University of San Francisco for four years, teaching organic and medicinal chemistry. He earned his Ph.D. from Indiana University and was a post-doctoral fellow at MIT.
